Clinical Trial: Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 Symptoms

U.S., June 25 -- ClinicalTrials.gov registry received information related to the study (NCT07664696) titled 'Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 Symptoms' on June 02.

Brief Summary: Investigational New Drug trial investigating safety as primary endpoint and clinical efficacy as secondary endpoint of placental, mesenchymal stem cell-derived extracellular vesicles for the treatment of COVID-19 symptoms in adults with mild to moderate illness.

Study Start Date: Jan., 2027

Study Type: INTERVENTIONAL

Condition: COVID-19

Intervention: BIOLOGICAL: IV infusion using an isolated, placental, mesenchymal stem cell derived EVs

Single IV infusio...